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ABSTRACT
Dysregulated post-translational modification provides a source of altered self-
antigens that can stimulate immune responses in autoimmunity, inflammation, and 
cancer. In recent years, phosphorylated peptides have emerged as a group of tumour-
associated antigens presented by MHC molecules and recognised by T cells, and 
represent promising candidates for cancer immunotherapy. However, the impact of 
phosphorylation on the antigenic identity of phosphopeptide epitopes is unclear. 
Here we examined this by determining structures of MHC-bound phosphopeptides 
bearing canonical position 4-phosphorylations in the presence and absence of their 
phosphate moiety, and examining phosphopeptide recognition by the T cell receptor 
(TCR). Strikingly, two peptides exhibited major conformational changes upon 
phosphorylation, involving a similar molecular mechanism, which focussed changes 
on the central peptide region most critical for T cell recognition. In contrast, a third 
epitope displayed little conformational alteration upon phosphorylation. In addition, 
binding studies demonstrated TCR interaction with an MHC-bound phosphopeptide 
was both epitope-specific and absolutely dependent upon phosphorylation status. 
These results highlight the critical influence of phosphorylation on the antigenic 
identity of naturally processed class I MHC epitopes. In doing so they provide a 
molecular framework for understanding phosphopeptide-specific immune responses, 
and have implications for the development of phosphopeptide antigen-specific cancer 
immunotherapy approaches.
INTRODUCTION
MHC-restricted phosphopeptides represent 
promising tumour-associated antigens for cancer 
immunotherapy. Phosphopeptide antigens are naturally 
processed and presented on human tumour cells by class 
I and class II MHC molecules [1–5]. Consistent with 
the prevalence of phosphorylation, phosphopeptides are 
presented by multiple MHC molecules [1, 4, 5], and may 
comprise a substantial portion of the peptide repertoire 
for some alleles. Initial mass spectrometric analysis 
of phosphopeptide presentation highlighted different 
patterns of expression on separate tumour cell lines 
[1, 5], suggesting distinct tumour-specific immunological 
signatures of “transformed self”. Furthermore, 
phosphopeptide-specific  T  cells  can  recognize  intact 
human tumour cells [1, 4, 5], highlighting their therapeutic 
potential. Moreover, phosphopeptide antigens may be 
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closely linked to maintenance of the malignant phenotype. 
Dysregulated protein kinase activity, normally tightly 
controlled, is a hallmark of malignant transformation, 
and contributes directly to oncogenic signalling pathways 
leading to uncontrolled proliferation, cell survival, 
tissue invasion and metastasis [6–10]. Secondly, the 
source proteins for phosphopeptide antigens include 
those involved in cytoplasmic signalling pathways, 
metabolism, or cell cycle regulation, many of which are 
implicated in cellular transformation [1, 4, 5]. Consistent 
with this, we recently identified numerous phosphopeptide 
antigens selectively presented on primary haematological 
malignancies, many of which were immunogenic and 
might contribute to tumour immunosurveillance [11]. 
These  factors  suggest  phosphopeptide  antigens  may 
provide functionally important targets for cancer 
immunotherapy.
Despite their potential clinical relevance, the 
influence of phosphorylation on the antigenic identity of 
naturally occurring phosphopeptides is currently unclear. 
One possibility, supported by recent structural data [12], 
is that the conformation of MHC-bound phosphopeptide 
epitopes  closely  matches  that  of  their  unmodified 
counterparts.  In  this  case  phosphopeptide-specific 
immunotherapy  strategies  such  as  TCR  gene  transfer 
would  ideally  focus  not  only  on  the  specific  antigenic 
peptide  target,  but  also  significantly  on  the  phosphate 
moiety itself. A second possibility is that phosphorylation 
might  profoundly  influence  the  MHC-bound 
phosphopeptide conformation, creating conformationally 
novel antigens. This could increase therapeutic targeting 
options,  which  include  vaccination  and  adoptive  T 
cell transfer approaches [13, 14]. However such major 
conformational changes have not been demonstrated to 
date. Finally, although phosphopeptide recognition by 
T cells  in vitro  is  observed  to  be  both  epitope-specific 




Although our previous studies on class I MHC 
phosphopeptide presentation did not address these issues, 
they established that the phosphate group can strongly 
influence  peptide-MHC  (pMHC)  interaction  [15].  We 
defined a canonical motif,  involving a phosphorylation 
at position 4 and a positively charged side chain at 
position 1 (R/K), accounting for ~ 50% of the HLA-A2 
phosphopeptide  repertoire.  This  motif  was  frequently 
associated with subdominant anchor residues. For 
phosphopeptides  with  this  canonical  motif  (hereafter 
referred to as canonical phosphopeptides), the phosphate 
moiety could act as a “phosphate surface anchor”, 
mediating extensive contacts to HLA-A2. Furthermore, 
phosphate-mediated contacts were highly energetically 






and their non-phosphorylated counterparts, and assessed 
the  effects  of  phosphorylation  on  pMHC  affinity. 
Also, we studied the ability of the TCR to discriminate 
phosphorylated  from  unmodified  forms  of  the  same 
naturally  occurring  epitope,  using  a  soluble TCR  from 
a  functionally  phosphopeptide-specific  T  cell  clone. 
Our results suggest phosphorylation can exert a critical 
influence  on  both  epitope  conformation  and  TCR/
pMHC binding, and highlight the possibility of targeting 
specific  tumour  associated  phosphopeptides  for  cancer 
immunotherapy. 
RESULTS
Assessing the structural effect of 
phosphorylation on three HLA-A2-bound 
phosphopeptides
Previously, we noted that canonical phosphopeptides 
exhibited a restrained main chain conformation around 
the  position  4  Cα  compared  to  non-phosphorylated 
peptides [15]. Although consistent with phosphorylation-
induced conformational changes, this analysis did not 
compare the same peptides in their phosphorylated/non-
phosphorylated states, and an alternative explanation 
was that canonical phosphopeptides are restricted to 
those that naturally adopt this restrained conformation 
in the unmodified state. The only study to make a direct 
comparison [12] established that a single canonical motif 
phosphopeptide did not alter in conformation in the 
unmodified state. However, the presence of a Proline close 
to the phosphate in this epitope prevented it adopting the 
restrained conformation of previously solved canonical 
phosphopeptides, suggesting it may be atypical of 
canonical phosphopeptides (Figure 1A).
To address this, we determined HLA-A2 complex 
structures of three canonical phosphopeptide antigens 
(RQApSlSISV, termed PKD2 and derived from Protein 
Kinase  D2;  RQApSIELPSMAV,  termed  RQA_V  and 
derived  from  Lymphocyte  Specific  Protein  1  (LSP-1);  
RQIpSQDVKL,  termed  RQI  and  derived  from 
adenosine monophosphate  deaminase  2  (AMPD2))  [5] 
in both phosphorylated and non-phosphorylated states 
(Supplementary  Table  1).  We  observed  well-defined 
electron density for each peptide moiety (Figure 2). These 
antigens  are  attractive  therapeutic  targets,  as  PKD2  is 
dysregulated in several solid tumours, implicated in the 
transformation process, and a target for chemotherapy 
[16];  LSP-1  is  a  marker  of  lymphoma  [17],  and  the 
RQA_V epitope is elevated on the surface of a range of 
tumour cell lines and primary leukemic tissue [11]; finally 
AMPD2 expression has been noted on both melanoma 
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Figure 2: Electron density for three HLA-A2 bound phosphopeptides in phosphorylated and unmodified states. 
(A)  Structure  of  PKD2p  (RQApSLSISV)  and PKD2np  (RQASLSISV)  (left  and  right,  respectively),  each  superimposed  on  a 2Fo-Fc 
electron density map contoured at 1.0 σ (blue wire). (B) Structure of RQA_Vp (RQApSIELPSMAV) and RQA_Vnp (RQASIELPSMAV) 
(left  and  right,  respectively),  pictured  as  in A.  (C)  Structure  of  RQIp  (RQIpSQDVKL)  and  RQInp  (RQISQDVKL)  (left  and  right, 
respectively), pictured as in A.
Figure 1: Analysis of main chain conformations of phosphopeptides. (A) Comparison of peptide main-chain conformation 
around position 4  for a canonical phosphopeptide derived from insulin  receptor substrate 2  (coloured blue; PDB code 3FQX obtained 




and ovarian carcinoma cell lines [5]. Unsurprisingly, 
each epitope structure adopted a restrained main chain 
conformation at the position 4 Cα in its modified form, 





A conformational change in PKD2 permits 
phosphorylation-dependent MHC binding
Typical  of  canonical  HLA-A2-restricted 
phosphopeptides that bear suboptimal anchors, the PKD2 
phosphopeptide exhibits phosphate-dependent binding to 
HLA-A2, with  its affinity higher  in  the phosphorylated 
state  (Kd  38.5  nM  vs  284.5  nM  for  modified  and 
unmodified  forms  respectively)  [15].  Comparisons 
of  HLA-A2-PKD2p  and  HLA-A2-PKD2np  (both  in 
P212121, Supplementary Table 1) revealed a very similar 
overall MHC conformation, with an rmsd value of 0.21 
Å. In contrast, the same comparisons clearly showed a 
major change in epitope conformation (Figure 3A–3C), 





epitope adopts a raised conformation at position 4 enabling 
additional phosphate-mediated MHC and intra peptide 
contacts, typical of canonical phosphopeptides (Figure 3B, 
Figure  3D,  left).  Most  importantly,  phosphorylation 
results in major reorientation of the main chain and side 
chains at residues 5, 6 and 7 (Figure 3C), positions that 
frequently contact the TCR. Consequently, the molecular 
surface  presented  for  T  cell  recognition  by  HLA-A2-
PKD2p and HLA-A2-PKD2np is substantially different. 
The conformational change also provides an explanation 
for  the  effect  of  phosphorylation  on PKD2  affinity  for 
HLA-A2: although the differing main chain conformations 
alter pMHC contacts, the net energetic effect is likely 
minimal, other than the additional p-Ser-mediated MHC 
contacts, which most probably underlie the stronger HLA-
A2-PKD2p interaction.
The RQA_V epitope undergoes a radical 
conformational rearrangement upon 
phosphorylation
We  also  examined  the  structure  of  RQA_V,  a 
12-residue phosphopeptide [5], in both phosphorylated and 
non-phosphorylated  forms. Although RQA_V possesses 









initially hypothesised that the presence of two additional 
C-terminal  amino  acids  in  RQA_V  might  disrupt 
phosphate-mediated contacts to the MHC molecule. 
However, the structure of the phosphorylated form of 




showed  were  highly  energetically  significant  [15].  In 
fact, the additional two residues were accommodated 
via a novel helical segment towards the C terminus of 
the phosphopeptide (Figure 4A, left). This suggested an 




the strength of pMHC binding.
To test this, we solved the structure of RQA_Vnp 
in  complex  with  HLA-A2  (HLA-A2-RQA_Vnp).  We 
failed  to  crystallize  the  HLA-A2-RQA_Vnp  complex 
using conventional approaches, even in conditions used 
to crystallise a wide range of HLA-A2 complexes [12]. 
To  circumvent  these  problems,  we  co-crystallized  the 
unmodified complex in the presence of LILRB1 (LIR-1,  
ILT2) [18], a broadly expressed inhibitory receptor that 
recognises  class  I  MHC  with  low  affinity  and  which 
we have previously co-crystallised in complex with 
HLA-A2  [19].  Crucially,  the  LILRB1  binding  site  on 
HLA-A2  involves  the  α3  and  β2m  domains  but  does 
not  involve  the  α1-α2  peptide-binding  platform  [19], 
and  peptides  crystallised  in  HLA-A2  are  identical  in 
conformation  in  the  presence  or  absence  of  LILRB1 
[19,  20].  Crystallisation  trials  of  HLA-A2-RQA_Vnp 
with  LILRB1  yielded  LILRB1-HLA-A2-RQA_Vnp 







complexes show little difference in overall MHC structure 
(rmsd 0.75Å). In RQA_Vnp, S4 adopts a low conformation 
in the binding groove forming no interactions with 
surrounding residues (Figure 4D, right), but as for PKD2, 
phosphorylation results in a raising of the main chain at 
this position, permitting extensive phosphate-mediated 
contacts  to HLA-A2 (Figure 4D,  left).   Also similar  to 
PKD2, the resulting conformational change is focussed 
on  the  central  region  of  the  RQA_V  epitope  likely  to 
be most critical  for T cell  recognition (Figure 4B–4D),  
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with substantial differences in both main chain position 
and individual side chain orientations at residues 4, 5 and 
7, frequently sites of TCR contact (Figure 4C). As a result, 
the molecular surface presented for T cell recognition by 
RQA_Vp  (Figure  4E,  left)  and RQA_Vnp  (Figure  4E, 
right) epitopes is substantially different.
Comparison of RQA_Vp and RQA_Vnp structures 
also  explains  their  equivalent  affinities  for  HLA-A2. 
Although  RQA_Vnp  lacks  any  S4-mediated  MHC 
contacts, the low main chain position allows additional 
side chain interactions and intra-peptide contacts, which 
help  stabilise  the  complex  (Figure  4F,  Supplementary 
Table  2).  Upon  phosphorylation  these  are  lost  due  to 
the  phosphate-induced  elevation  of  the  position  4  Cα, 
which results in a more raised peptide conformation 
(Figure 4F). Therefore, the conformational change permits 
energetically rich phosphate-mediated contacts to the 
MHC, but this is balanced by loss of interactions specific 
for  the  unmodified  peptide  conformation,  resulting  in 
similar pMHC binding affinities.
The RQI epitope is preconfigured for phosphate-
dependent interaction with MHC
A  third  canonical  phosphopeptide  (RQI)  was 
solved in phosphorylated (RQIp) and non-phosphorylated 
(RQInp) forms in complex with HLA-A2, to 1.7Å (HLA-
A2-RQIp)  and  2.1Å  (HLA-A2-RQInp)  respectively 
Figure 3: Structural comparison of HLA-A2 bound PKD2 phosphopeptide in modified and unmodified states. (A) 
HLA-A2  bound  structures  of  PKD2p  (left,  red)  and  PKD2np  (right,  blue).  The  α1-α2  antigen  binding  platform  is  shown  in  ribbon 
representation  (pink),  with  α2  helix  residues  137-166  omitted  for  clarity.  (B)  Superposition  of  the  PKD2  main  chain  structures  for 
phosphorylated (red) and non-phosphorylated (blue) peptides, including the R1 and S4/p-Ser side-chains. (C) Side-chain orientation for 







enhanced  binding  to  HLA-A2  relative  to  RQInp  (Kd 
25.5 nM versus 1925 nM, respectively). As with previous 




(rmsd  0.39Å,  Figure  5A–5C),  although RQIp  exhibited 
phosphate-mediated  contacts  (Figure  5D,  left)  similar 




main chain conformation of its phosphorylated counterpart, 
suggesting that, other than the phosphate moiety, the 
antigenic  features  exposed  to  the  TCR  would  be  very 
similar for RQIp and RQInp (Figure 5E).
Two  key  reasons  underlie  these  observations. 
Firstly,  in  HLA-A2-RQInp,  residues  E63  and  K66 
from the α1-helix interact with one another and form a 
cooperative stabilising hydrogen-bonding network with 
the peptide backbone amide and carbonyl groups of 
Q2 (Figure 6A,  left). This arrangement  is conserved  in 




mediated contacts elevate the main chain conformation 
around positions 4–5. Although these are lost in RQInp, 
an elevated main chain conformation around position 4 is 
stabilised critically by H70, which protrudes from the base 
of the α1 helix and reorientates relative to its position in 
the phosphopeptide structure, enabling stabilising contacts 
to the backbone carbonyl of peptide residues at positions 

















of its phosphorylated counterpart, and suggest that, other 
than the phosphate moiety, the antigenic features exposed 
to the TCR would be very similar for RQIp and RQInp 
(Figure 5).
TCR binding to a human CDC25b-derived 
phosphopeptide is highly phosphate dependent 
and epitope-specific
Having established that phosphorylation has diverse 
effects on epitope structure, we aimed to test whether a 
phosphorylated epitope could be distinguished from 
its  unmodified  counterpart  by  the TCR. We previously 
generated  phosphopeptide-specific  CD8+  T  cells  by 
immunising mice expressing a transgenic recombinant 
HLA-A*0201  molecule  (AAD)  with  activated  bone-
marrow-derived dendritic cells pulsed with synthetic 
phosphopeptides corresponding to those naturally 
presented on the surface of human tumour cell lines [5]. 
Despite the ability to isolate functional phosphopeptide 
specific T-cells, attempts to generate clonal populations 
of RQA_V specific T-cells for TCR isolation or produce 




recognised a phosphopeptide epitope derived from the 
CDC25b protein (GLLGpSPVRA, subsequently termed 
GLLGpS)  of  sufficient  quality  for  surface  plasmon 
resonance analysis. Previous structural analyses have 
indicated  that  the  GLLGpS  epitope  undergoes  only 
very minor alterations in main chain conformation [12], 
suggesting it would provide a relatively demanding test of 
phosphate-dependent recognition by the TCR. 
Injection  of  HLA-A2-GLLGpS  complex  over 
immobilised  TCRpCDC25b  yielded  substantially 
higher responses than over control surfaces (LDN5 and 
streptavidin), indicating specific binding (Figure 7A, left). 
In  contrast,  injection  of  HLA-A2  containing  GLLGS, 
lacking the phosphorylation at position 5, resulted in 
equivalent  responses  over  immobilised  TCRpCDC25b 
and  control  surfaces  (Figure  7A,  middle),  indicating 
that  recognition  of  GLLGpS  by  TCRpCDC25b  was 
entirely dependent on the presence of the phosphate. 
To  investigate  if  recognition  was  dependent  on  the 
GLLGS  amino  acid  sequence,  we  also  tested  binding 
of  immobilised  TCRpCDC25b  to  HLA-A2  containing 
a different phosphopeptide featuring a p-Ser at position 
5  (SLLTpSPPKA  (termed  SLLTpS)  derived  from 
Thyroid  hormone  receptor  interacting  protein  12)  [5]. 
Injection of HLA-A2-SLLTpS complex yielded identical 
responses  over  TCRpCDC25b  and  control  surfaces 
(Figure 7A, right), indicating recognition of GLLGpS by 
TCRpCDC25b  was  not  only  phosphate-dependent  but 
also  peptide  sequence-specific. We  then  measured  the 
strength  of  TCRpCDC25b  phosphopeptide  recognition 
by  equilibrium  affinity  analysis,  repeating  injections 
of  HLA-A2-GLLGpS  over  a  range  of  concentrations 








and  labelled  green.  (E) Molecular  surface  of  phosphorylated  (left)  and  non-phosphorylated  (right) RQI  peptides,  as  viewed  from  the 
perspective of the TCR. Color scheme as in Figure 4D.
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(Figure  7B).  These  experiments  indicated  an  affinity 
(Kd)  of  ~40.1  μM  (Figure  7B).  Similar  injections  and 
equilibrium binding analysis in the opposite orientation, 
confirmed both the specificity and affinity (Kd ~35.1 μM) 
of  the  interaction (Figure 7C).  In both orientations,  the 







Phosphopeptides are emerging as an important 
group of MHC-associated antigens that may be of 
particular relevance in the context of cancer. Consistent 
with dysregulation of kinase pathways in cancer, our 
recent work in the context of haematological malignancies 
identified numerous phosphopeptide species selectively 
presented on tumour tissue but absent on matched normal 
tissue, and also indicated that in many cases the source 
proteins for such tumour-associated phosphopeptides are 
encoded by oncogenes strongly linked to leukemogenesis, 
highlighting their potential as immunotherapeutic 
targets [11]. Furthermore, whereas robust CD8+ immunity 
against many such phosphopeptides was observed in 
healthy individuals, immunity was impaired in leukaemia 
patients,  particular  those with  a  poor  prognosis. These 
findings implicate immunity to phosphopeptide antigens in 
tumour immunosurveillance, and highlight their potential 
importance in future cancer immunotherapy strategies 
such  as  tumour  vaccines  and  T  cell  adoptive  transfer 
approaches. In this context, gaining a solid understanding 
of the potential molecular effects of phosphorylation on 
epitope conformation and TCR interaction is a priority, 
and could impact on the choice of targeting strategy. 
Our study establishes that phosphorylation can have 
radical effects on the antigenic identity of MHC-bound 
peptides. We show that phosphorylation can have major 
effects on peptide conformation, and outline the structural 
basis of this effect. For both PKD2 and RQA_V epitopes, 
a similar structural mechanism was involved. Interestingly, 
despite this, the overall consequences for pMHC affinity 
Figure 6: Molecular contacts stabilising the main chain conformations of RQI, PKD2 and RQA_V epitopes. (A) 





were clearly highly context dependent, and emphasise the 
benefit of parallel structural and pMHC affinity analyses 
to fully understand the effects of phosphorylation on 
individual  epitopes.  We  and  others  have  previously 
established the molecular “ground rules” for canonical 
phosphopeptide presentation by MHC molecules 
based  on  extensive  structural,  peptide-MHC  affinity 
and  mutagenesis  approaches  [12,  15].  These  studies 
Figure 7: Epitope-specific and phosphate-dependent recognition of HLA-A2-GLLGpS. (A) Injection of HLA-A2-GLLGpS 
at different concentrations indicated specific binding to CDC25b-specific TCR (left panel), whereas neither injection of HLA-A2-GLLGS 
(middle  panel)  nor HLA-A2-SLLTpS  (right  panel)  resulted  in  specific  binding.  (B)  Scatchard  analysis  of HLA-A2-GLLGpS  binding 






demonstrated that the phosphate moiety is an integral part 
of the epitope, mediating energetically significant contacts 
to positively charged MHC residues, and explained how 
phosphorylation can substantially enhance the binding of 
peptides that exhibit low affinities for MHC.  Importantly, 
for the current set of canonical phosphopeptide antigens 
presented in this study, the phosphate mediated contacts to 
the MHC are highly conserved with previously determined 
canonical phosphopeptide-HLA-A2 structures, suggesting 
that the same molecular “ground rules” are likely to apply, 
particularly with respect to the energetics of the phosphate 
mediated stabilisation of the MHC.
For PKD2, the conformational change resulted in 






cases, the resulting changes in main chain conformation 
were focussed on the central region of each epitope and 
thus would be expected to have critical effects on TCR 
recognition [20, 22]. Consistent with this, Cobbold et al 
generated  T  cells  that  recognise  the  RQA_V  epitope 
in  both  a  phosphate-dependent  and  epitope-specific 
manner [11]. Phosphorylated epitopes such as these 
cannot therefore be regarded as merely conventional 
peptide epitopes with “cherries on top”. Rather, in terms 
of their conformation a subset of phosphopeptides are 
completely novel. Such “conformational neoantigens” 
may be particularly likely to occur within the canonical 
phosphopeptide repertoire, since the mechanism 
underlying epitope rearrangement appears to be driven by 
the phosphorylation at position 4, which introduces novel 
contacts to the class I MHC [15]. This mechanism may 
operate for many other canonical phosphopeptides. 
Secondly, in contrast to the situation above, many 
phosphopeptides, including other canonical epitopes, 
may  naturally  adopt  conformations  in  the  unmodified 
state  that  (upon  phosphorylation  at  position  4)  allow 
classic  phosphate-mediated  contacts,  and  consequently 
no/little conformational change would be expected upon 
modification. The proportion of canonical phosphopeptides 
in this category is unclear, but this group includes both 
RQIpS,  and  the  RVApS  phosphopeptide  derived  from 
Insulin Receptor Substrate 2 [5, 12]. Moreover, many non-
canonical phosphopeptides may remain conformationally 
unaltered. 
Our surface plasmon resonance binding studies, the 
first  analysis  of TCR  interaction with  phosphopeptide-
MHC complexes, build on these findings. They establish 
that  the ability of T cells  to  recognise phosphopeptide-
MHC  molecules  in  both  an  epitope-specific  and 
phosphate-dependent manner can reside within the TCR 
itself,  and  that  TCR  discrimination  between  modified/
unmodified forms can be essentially complete. Moreover, 
our studies highlight the presence of the phosphate moiety 
can be sufficient to enable such modification-dependent 
and antigen-specific discrimination even for epitopes in 
which phosphorylation-induced conformational alterations 
are minimal,  as  for  the GLLGpS  epitope we  focussed 
on. The finding that a single phosphorylation can make 
such  a  dramatic  difference  to  the  biophysics  of  TCR/
pMHC interaction provides hope that even in the absence 
of conformational change, altered phosphorylation, 
for example during different stages of oncogenesis, 
has a profound effect on antigenic identity and may be 
sufficient  to  break  T  cell  tolerance,  thereby  inducing 
post-translational-modification-dependent  immune 
responses. In addition, previous studies have highlighted 
that  pCDC25b-specific CD8+ T  lymphocytes  displayed 
effector functions against target cells pulsed with epitopes 
corresponding to the phosphorylated forms of the 
antigen  but  not  the  non-phosphorylated  equivalent  [5]. 
Our findings that the pCDC25b-specific TCR bound the 
phosphorylated but not the non-phosphorylated form of the 




effects of phosphorylation on epitope structure are diverse. 
For  individual peptides,  such as  the canonical RQA_V 
epitope studied here, these can include radical changes in 
peptide conformation, including in central regions likely 
to influence TCR recognition. Consistent with this, T cells 
specific  for  the  RQA_V  peptide  isolated  from  healthy 
donors were found to distinguish the phosphorylated from 
the non-phosphorylated form of the epitope [11]. For other 
peptides, the effects of phosphorylation on conformation 







phosphorylations are also oriented towards the central P5 
position. However, given that TCR recognition is typically 
focussed substantially on such central peptide residues, it 
is likely that, in the absence of phosphorylation-induced 
changes in epitope conformation, phosphorylations at 
extreme ends of the peptide may often be ignored during 
T cell recognition. 
Our results therefore provide a basis for 
understanding phosphopeptide-specific immune responses 
observed in healthy individuals and cancer patients 
[11], and provide additional impetus for therapeutic 
targeting of phosphopeptides as candidate antigens for 
cancer immunotherapy. Recent studies have highlighted 
mutated cancer neoantigens as a target for potent 
anti-tumour immune responses [23], particularly for 
tumours/tumour  subtypes  with  high mutational  burden 
Oncotarget11www.impactjournals.com/oncotarget
(e.g. melanoma, lung). However, for the many tumours 
and tumour subtypes with relatively low mutational 
burden,  alternative  antigenic  targets  may  be  required. 
Given the widespread oncogene-driven dysregulation of 
kinase pathways in such low mutation groups, therapeutic 
targeting of the cancer phenotype via tumour-associated 
phosphopeptide antigens remains an attractive alternative 
possibility.
In general, such targeting strategies should 
specifically  target  the  phosphorylated  form  since  these 
are likely to be upregulated on transformed cells, 
whereas  unmodified  counterparts  may  be  present  on 
normal  untransformed  cells.  Our  findings  that  such 
phosphorylated forms are highly antigenically distinct 
from their unmodified counterparts establish a molecular 
basis for antigen-specific targeting of such phosphorylated 
forms, for example employing either vaccination [14] or 
adoptive T cell transfer [13]. In principle, phosphorylation-
induced conformational neoantigens may be particularly 
attractive targets, as their altered conformation could 
circumvent central tolerance, potentially increasing the 
size of the T cell repertoire responding to vaccination.  In 
comparison, the T cell repertoire capable of recognising 
phosphopeptides unaltered in conformation by their 
modification may be  somewhat narrower due  to T  cell 
tolerance;  potentially  favouring  TCR  gene  transfer 
approaches employing highly selected TCRs that display 
phosphate-dependent recognition. In this context, the 
RQA_V  and  PKD2  phosphopeptides  we  describe  are 
attractive targets for vaccination and TCR gene transfer 
approaches.  Notably,  not  only  does  RQA_V  exhibit 
a dramatic phosphorylation-induced conformational 
rearrangement, but we have recently detected presentation 
of HLA-A2-RQA_Vp on primary tumour samples from 
a range of human leukemias and were able to generate 
human  T  cells  recognising  RQA_V  in  an  epitope-
specific  and  phosphate-dependent  manner  (10).  In 
combination, these features highlight conformationally 
unique phosphopeptides such as RQA_V as compelling 
candidates for cancer immunotherapy approaches.
MATERIALS AND METHODS
Class I MHC production and crystallisation
HLA-A2  heavy  chain  and  β2-microglobulin  were 
expressed in E. coli,  purified  from  inclusion  bodies  and 
refolded together with synthetic phosphopeptide or 








crystals that typically grew to 200 mm × 200 mm × 100 mm 
after  3–4  days.  Crystals  of  HLA-A2  in  complex  with 
phosphorylated/non-phosphorylated  forms  of  PKD2 were 
grown as described [12].
Crystallisation of HLA-A2-RQA_Vnp in 
complex with LILRB1
For  crystallization  of  the  HLA-A2-RQA_Vnp 







18%  PEG  3350,  0.2M  ammonium  acetate  and  0.1M 
HEPES pH 7.4, yielded diffraction-quality crystals that 
grew to ~ 300 mm × 200 mm × 200 mm after 2–3 weeks.
Peptide-MHC data collection, structure solution 
and refinement
HLA-A2-peptide  complex  crystals  were  soaked 
in reservoir buffer containing increasing concentrations 
(5%, 10% and 15% (v/v)) of ethylene glycol or glycerol 
before  being  ‘flash-cooled’  at  100K  in  a  nitrogen  gas 
stream (Oxford Cryosystems). X-ray data were collected 
to  1.6–2.7Å  on  an  “in  house”  MicroMax  007HF 
microfocus  rotating  anode  X-ray  generator  (Rigaku) 
with a Saturn CCD detector. Data sets were integrated, 
scaled and merged with  the XDS suite  [25]. HLA-A2-
peptide complex structures were determined by molecular 
replacement with MOLREP [26] using as the search model 
a previously determined HLA-A2 structure with peptide 
residues  omitted.  The  LILRB1-HLA-A2-RQA_Vnp 
complex structure was solved by molecular replacement 
with CNS [27] using LILRB1-HLA-A2 complex as the 
search model [19].
Molecular-replacement calculations yielded 
unambiguous rotation and translation function solutions. 
The molecular models were refined with CNS [27] and 




maps showed unbiased features in the electron density 
(full sequence of each peptide), confirming the validity of 
the molecular replacement solution. Model manipulations 
were  performed  with  COOT  [29].  Once  the  R  factor 
values were below 30%, water molecules were included 
if they appeared in Fo – Fc maps contoured at over 3σ 
and were within hydrogen-bonding distance to chemically 
acceptable  groups.  The  final  data  processing  and 
refinement statistics are listed in Supplementary Table 1. 
The  quality  of  the  final  refined  models  was  verified 
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with PROCHECK [26] and WHATCHECK [30]. Most 
residues were well  defined  in  all  structures,  except  for 
a few solvent-exposed side chains. Hydrogen bonding, 
hydrophobic and van der Waals contacts were analyzed 
with  CONTACT  (CCP4)  [26].  Structural  figures  were 
produced  with  Pymol  (http://www.pymol.org),  or  with 
the  POVScript  program  [31]  and  rendered  with  the 
Persistence of Vision Raytracer (http://www.povray.org), 
with molecular surfaces generated using DelPhi [32]. 
Peptide-MHC affinity assays
HLA-A2  heavy  chain  was  expressed  in  E. coli, 
refolded with  β2M and  the  peptide NLVPMVATV,  and 
purified as described above. Competitive peptide binding 
assays were  carried out  as  described  [33]. Test  peptide 
concentrations covered a 100,000-fold range, with 
each concentration assayed in triplicate. MHC-peptide 
complexes were captured on microplates coated with 
monoclonal antibody W6/32 (to human HLA) and washed, 




less than the concentration of MHC and the IC50 is greater 
than or equal to the concentration of MHC), the IC50 is a 
reasonable approximation of the dissociation constant [34].
TCR/peptide-MHC binding assays
Experiments utilised a BIAcore 3000 and HBS-EP  
buffer,  at  a  flow  rate  of  10  µl.min−1.  For  HLA-peptide 
injections,  recombinant  TCRs  were  produced  in  the 
Drosophila expression system incorporating C-terminal 
biotinylation tags, biotinylated in vitro  using BirA,  and 
immobilised to streptavidin-coated CM5 surfaces. In 
the  reverse  orientation,  purified  Drosophila-expressed 
CDC25b-specific  TCR  was  injected  over  streptavidin-
coated  surfaces  to  which  biotinylated  HLA-peptide 
complexes (either HLA-A2-GLLGpS or control complexes, 
incorporating  C-terminal  biotinylation  tags)  were 
immobilised. Data were analysed using BIAevaluation 3.1 
and Origin graphing software.
Accession numbers
Atomic coordinates and structure factors are 
deposited in the Protein Data Bank under accession numbers 
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